Neuro Covid
Global Health Challenge Ecosystem
Neuro COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), represents a complex and multifaceted condition that affects individuals recovering from COVID-19. Characterized by persistent neurological symptoms such as cognitive impairment, memory issues, and mood disturbances, Neuro COVID can significantly disrupt daily life and overall well-being. These symptoms often persist long after the acute phase of the illness has resolved, leading to challenges in both personal and professional spheres.
Data-driven research plays an increasingly vital role in understanding Neuro COVID. By systematically collecting and analyzing data on patient experiences, symptom progression, and treatment responses, researchers aim to uncover patterns that could lead to more effective and personalized interventions. Collaborative efforts among healthcare providers, researchers, and patient advocates are essential to developing comprehensive care strategies. These efforts not only aim to alleviate the burden of Neuro COVID but also to enhance the overall support system for individuals navigating this challenging condition, paving the way for improved health outcomes and quality of life.
Global Perspective
From a global perspective, Neuro COVID poses a significant public health challenge, with varying impacts across regions. This condition, affecting millions worldwide, manifests as persistent neurological symptoms such as cognitive issues and fatigue, often extending long after the acute phase of COVID-19. In high-income countries, increasing awareness and advanced healthcare systems support better diagnosis and management of Neuro COVID. However, disparities remain, including differences in diagnostic capabilities and treatment access.
In contrast, low- and middle-income countries face greater challenges due to limited healthcare resources and lower awareness, leading to underdiagnosis and inadequate treatment options. This global disparity highlights the need for coordinated international efforts to address Neuro COVID.
Enhancing global awareness, improving diagnostic tools, and expanding treatment accessibility are crucial. Collaborative efforts among researchers, healthcare providers, and advocacy groups are essential to bridge these gaps. Public health initiatives focusing on education, early recognition, and support can help alleviate the burden of Neuro COVID worldwide, aiming for improved outcomes and quality of life for all affected individuals.
Neuro Covid Global Challenge Ecosystem
Neurological deficits and psychiatric complications are recognised in patients with COVID-19. Symptoms are diverse and difficult to predict, and little is known about which cell types in the brain are directly or indirectly affected by SARS-CoV-2 infection. The long-term complications of COVID-19 (LongCOVID or Post-COVID syndrome, we refer here to Post-COVID) are not restricted to severe COVID-19 cases but have been demonstrated in over half of all patients at six months following primary infection. Several large retrospective cohorts have reported an increase specifically for neurological and neuropsychiatric complications at six months following COVID-19 with incidences as high as 33-49%. Neurological symptoms during Post-COVID are incredibly broad, including ischemic stroke and even involvement of the peripheral nervous system.
1800+
Clinic Trials
400+
Top Clinics
1200+
Investors
20000+
Data Points
​
Neuro COVID in Charts
The chart depicts the projected growth of efforts to address Neuro COVID from 2019 to 2025, demonstrating a consistent and significant upward trend. Starting at a baseline of approximately 45 units in 2019, the efforts steadily increase to about 50 units by 2021, reflecting a growth of roughly 10%. This upward momentum continues, with efforts expanding to around 55 units by 2023, marking a 20% increase from the initial level. By 2025, the projection reaches nearly 70 units, indicating a total increase of about 55% over the period. This continuous rise highlights the growing global focus and intensification of initiatives to understand, manage, and treat Neuro COVID, driven by advances in research, resource mobilization, and international collaboration.
Solution to Neuro COVID
Addressing global Neuro COVID challenges requires a comprehensive approach. Key strategies include improving early detection, enhancing access to effective treatments, and developing robust healthcare support systems. Promoting research into the neurological impacts of COVID-19 and potential therapies, along with fostering global collaboration on data sharing and policy development, can drive significant progress. These combined efforts aim to improve patient outcomes, reduce disparities, and enhance the quality of life for those affected by Neuro COVID worldwide.
At DKG, we are committed to tackling global Neuro COVID challenges through a holistic approach. Our strategies prioritize advancing early detection, improving access to effective treatments, and strengthening healthcare support systems.
Neuro COVID Global Challenge Ecosystem Dashboard
The Neuro COVID Global Challenge Ecosystem Dashboard stands at the forefront of market intelligence, offering an expansive suite of services to fulfill the diverse needs of its users. It serves as the go-to platform for comprehensive benchmarking, providing insights into organizations, technologies, and competitive landscapes.
Boasting coverage of over 500+ clinical trials, 1000+ organizations, 1100+ investors, and an extensive database comprising 12000+ data inputs within the Neuro COVID sector, this dashboard is unparalleled in its depth and breadth of information. Whether navigating environmental research, exploring investment opportunities, users can rely on this dashboard as their trusted source of intelligence and analysis.
Neuro COVID Journey Map
The Neuro COVID Global Challenge Ecosystem is a structured nine-stage framework aimed at tackling the worldwide impact of Neuro COVID. It begins with establishing a global focus and enhancing surveillance, followed by data aggregation and impact analysis to inform strategies. The approach then develops a strategic plan, mobilizes resources, and implements targeted interventions. Continuous assessment ensures effectiveness, leading to the creation and implementation of long-term policies.
Strategic Partners Projects
Global Medical Clinics Dashboard
GMC Big Data Analytics Dashboard serves as a one-stop platform for all market and business intelligence operations its users may need, including benchmarking for companies, technologies, competitive and SWOT analysis for more than 9,110 international medical clinics.
The Dashboard aggregates data from about 11,200 healthcare-related entities divided into 8 main categories and distributed across various regions. Based on this data, the Dashboard provides users with tools for conducting market intelligence, analyzing industry trends, and delivering insights from analytics.
Deep Knowledge Group
Projects Platform
End-to-End platform to discover, become involved with, or invest in Deep Knowledge Group’s current scope of market-ready products and projects. Learn about, participate in and invest in Deep Knowledge Group's current portfolio of projects and products that are market-ready.
Longevity.International
Longevity.International is a first-of-its-kind, open-access, non-profit and decentralized Longevity Industry Knowledge and Collaboration platform with the aim of promoting a greater degree of synergy, efficient cooperation, and discussion among a variety of Longevity Industry participants and stakeholders, including companies, investors, non-profits, academic labs and R&D hubs, governmental bodies and policy makers.
AI in BioMed
A comprehensive platform AI in BioMed sheds light on the developing nexus between artificial intelligence and biotechnology. Access to ground-breaking AI frameworks, powerful investors, business leaders, well-known organizations, and state-of-the-art research facilities are all available through this complex center, which addresses a range of subjects from biomarkers and drug discovery to neurotech and space medicine.
Longevity Industry Analytics – Powered by Deep Knowledge Group
Longevity Industry Analytics is a subsidiary of Deep Knowledge Group, a data-driven consortium of commercial and non-profit organizations active on many fronts in the realm of DeepTech and Frontier Technologies (AI, Longevity, BioTech, Pharma, FinTech, GovTech, SpaceTech, FemTech, Data Science, InvestTech), ranging from scientific research to investment, entrepreneurship, analytics, consulting, media, philanthropy and more.
